COVID-19 in solid organ transplantation patients: A systematic review

Coronavirus disease (COVID-19) rapidly progresses to severe acute respiratory syndrome. This review aimed at collating available data on COVID-19 infection in solid organ transplantation (SOT) patients. We performed a systematic review of SOT patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The MEDLINE and PubMed databases were electronically searched and updated until April 20, 2020. The MeSH terms used were "COVID-19" AND "Transplant." Thirty-nine COVID-19 cases were reported among SOT patients. The median interval for developing SARS-CoV-2 infection was 4 years since transplantation, and the fatality rate was 25.64% (10/39). Sixteen cases were described in liver transplant (LT) patients, and the median interval since transplantation was 5 years. The fatality rate among LT patients was 37.5% (6/16), with death occurring more than 3 years after LT. The youngest patient who died was 59 years old; there were no deaths among children. Twenty-three cases were described in kidney transplant (KT) patients. The median interval since transplantation was 4 years, and the fatality rate was 17.4% (4/23). The youngest patient who died was 71 years old. Among all transplant patients, COVID-19 had the highest fatality rate in patients older than 60 years : LT, 62.5% vs 12.5% (p=0.006); KT 44.44% vs 0 (p=0.039); and SOT, 52.94% vs 4.54% (p=0.001). This study presents a novel description of COVID-19 in abdominal SOT recipients. Furthermore, we alert medical professionals to the higher fatality risk in patients older than 60 years. (PROSPERO, registration number=CRD42020181299)

Telemedicina en trasplante hepático. Revisión rápida de la literatura / Telemedicine in liver transplantation. Brief review of the literature

Introducción. La tecnología de la información y la comunicación en la atención en salud viene en aumento en Colombia, al igual que en el resto del mundo. El uso de la telemedicina para el manejo y seguimiento del paciente con patologías crónicas ha demostrado gran utilidad. En el área del trasplante hepático en particular, la telemedicina busca, entre otras cosas, reducir las dificultades de acceso a cuidados especializados. Objetivo. Identificar si la atención por telemedicina en pacientes con trasplante hepático tiene desenlaces clínicos similares en cuanto a mortalidad, rechazo del injerto y adherencia, comparada con la atención presencial. Metodología. Revisión rápida de la literatura en las bases de datos MEDLINE, EMBASE, LILACS, Cochrane, Web Of Science y Google Scholar con los términos telemedicina y trasplante hepático, sin límite temporal ni de idiomas. Se incluyeron estudios de corte transversal, ensayos clínicos de asignación aleatoria y cuasi-experimentales que evaluaran adherencia o complicaciones asociadas a trasplante hepático. La revisión de artículos y extracción de datos fue realizada en forma independiente por ambos autores y resumida en forma cualitativa. No se consideró metaanálisis dada la alta heterogeneidad prevista de los estudios. Resultados. Se incluyeron un total de cinco artículos, todos con alto riesgo de sesgos, cuyos estudios fueron realizados en centros de los Estados Unidos. Ninguno de ellos evaluó los desenlaces de mortalidad o rechazo del injerto. Se identificó adherencia a los seguimientos, similar a la atención tradicional. Un estudio demostró disminución significativa en la proporción de pacientes excluidos para ingresar al protocolo de trasplante. Conclusión. Se requieren estudios para determinar si la atención bajo telemedicina tiene desenlaces clínicos similares a la atención personal, durante el seguimiento de pacientes con trasplante hepático.

Introduction. Information and communication technology in health care is increasing in Colombia as in the rest of the world. The use of telemedicine for the management and monitoring of patients with chronic pathologies has proved to be very useful. Specifically, in the area of liver transplantation telemedicine seeks, among other things, to reduce the difficulties of access to specialized care. Objective. To identify whether care through telemedicine in patients with liver transplantation has similar clinical outcomes in terms of mortality, graft rejection and adherence, compared with face-to-face care. Methodology. Brief literature review in MEDLINE, EMBASE, LILACS, Cochrane, Web Of Science and Google Scholar databases with the terms telemedicine and liver transplantation, without time or language limitation. We included cross-sectional studies, randomized and quasi-experimental clinical trials that evaluated adherence or complications associated with liver transplantation. The review of articles and data extraction was carried out independently by both authors and summarized qualitatively. Meta-analysis was not considered given the high expected heterogeneity of the studies. Results. A total of five articles were included, all with a high risk of bias, in centers in the United States. None of them evaluated mortality outcomes or graft rejection. Follow-up adherence was identified similar to traditional care. One study showed a significant decrease in the proportion of patients excluded to enter the transplant protocol. Conclusion. Studies are required to determine if care through telemedicine has clinical outcomes similar to personal care, during the follow-up of patients with liver transplantation.

Trasplante hepático: evolución, curva de aprendizaje y resultados después de los primeros 300 casos / Liver transplantation: development, learning curve and results after the first 300 cases

Background: Liver transplantation (LT) is an option for people with liver failure who cannot be cured with other therapies and for some people with liver cancer. Aim: To describe, and analyze the first 300 LT clinical results, and to establish our learning curve. Material and Methods: Retrospective cohort study with data obtained from a prospectively collected LT Program database. We included all LT performed at a single center from March 1994 to September 2017. The database gathered demographics, diagnosis, indications for LT, surgical aspects and postoperative courses. We constructed a cumulative summation test for learning curve (LC-CUSUM) using 30-day post-LT mortality. Mortality at 30 days, and actuarial 1-, and 5-year survival rate were analyzed. Results: A total of 281 patients aged 54 (0-71) years (129 women) underwent 300 LT. Ten percent of patients were younger than 18 years old. The first, second and third indications for LT were non-alcoholic steatohepatitis, chronic autoimmune hepatitis and alcoholic liver cirrhosis, respectively. Acute liver failure was the LT indication in 51 cases (17%). The overall complication rate was 71%. Infectious and biliary complications were the most common of them (47 and 31% respectively). The LC-CUSUM curve shows that the first 30 patients corresponded to the learning curve. The peri-operative mortality was 8%. Actuarial 1 and 5-year survival rates were 82 and 71.4%, respectively. Conclusions: Outcome improvement of a LT program depends on the accumulation of experience after the first 30 transplants and the peri-operative mortality directly impacted long-term survival.

Validation of APACHE IV score in postoperative liver transplantation in southern Brazil: a cohort study / Validação do escore APACHE IV no transplante hepático pós-operatório no sul do Brasil: estudo de coorte

Abstract Background: Liver transplantation is the only curative therapeutic modality available for individuals at end-stage liver disease. There is no reliable method of predicting the early postoperative outcome of these patients. The Acute Physiology and Chronic Health Evaluation (APACHE) is a widely used model for predicting hospital survival and benchmarking in critically ill patients. This study evaluated the calibration and discrimination of APACHE IV in the postoperative period of elective liver transplantation in the southern Brazil. Methods: This was a clinical prospective and unicentric cohort study that included 371 adult patients in the immediate postoperative period of elective liver transplantation from January 1, 2012 to December 31, 2016. Results: In this study, liver transplant patients who evolved to hospital death had a significantly higher APACHE IV score (82.7 ± 5.1 vs. 51.0 ± 15.8; p < 0.001) and higher predicted mortality (6.5% [4.4-20.2%] vs. 2.3% [1.4-3.5%]; p < 0.001). The APACHE IV score showed an adequate calibration (Hosmer-Lemeshow - H-L = 11.37; p = 0.181) and good discrimination (Receiver Operator Curve - ROC of 0.797; Confidence Interval 95% - 95% CI 0.713-0.881; p < 0.0001), although Standardized Mortality Ratio (SMR = 2.63), (95% CI 1.66-4.27; p < 0.001) underestimate mortality. Conclusions: In summary, the APACHE IV score showed an acceptable performance for predicting a hospital outcome in the postoperative period of elective liver transplant recipients.

Resumo Introdução: O transplante de fígado é a única modalidade terapêutica curativa disponível para indivíduos com doença hepática terminal. Não há método confiável de prever o resultado pós-operatório imediato desses pacientes. A Avaliação da Gravidade da Doença Crônica e Aguda com bases Fisiológicas (APACHE) é um modelo amplamente usado para prever a sobrevida hospitalar e fazer a avaliação comparativa de pacientes criticamente enfermos. Este estudo avaliou a calibração e discriminação do APACHE IV no pós-operatório de transplante hepático eletivo no sul do Brasil. Métodos: Estudo clínico prospectivo de coorte em centro único que incluiu 371 pacientes adultos no pós-operatório imediato de transplante hepático eletivo de 1 de janeiro de 2012 a 31 de dezembro de 2016. Resultados: Neste estudo, pacientes com transplante hepático que evoluíram para óbito hospitalar obtiveram escore APACHE IV significativamente maior (82,7 ± 5,1 vs. 51,0 ± 15,8; p < 0,001) e mortalidade prevista mais alta (6,5% [4,4% -20,2%] vs 2,3% [1,4% -3,5%], p < 0,001). O escore APACHE IV mostrou uma calibração adequada (Hosmer-Lemeshow - H-L = 11,37; p = 0,181) e boa discriminação (Receiver Operator Curve - ROC de 0,797; intervalo de confiança de 95% - IC 95% 0,713-0,881; p < 0,0001), embora a taxa de mortalidade padronizada (Standardized Mortality Ratio - SMR = 2,63), (IC 95% 1,66-4,27; p < 0,001) subestime a mortalidade. Conclusões: Em resumo, o escore APACHE IV mostrou um desempenho aceitável para predizer um desfecho hospitalar no período pós-operatório de receptores eletivos de transplante hepático.

Transplante hepático na hepatite delta: experiência da América do Sul / Liver transplantation in hepatitis delta: south america experience

ABSTRACT BACKGROUND: The Amazon region is one of the main endemic areas of hepatitis delta in the world and the only one related to the presence of genotype 3 of the delta virus. OBJECTIVE: To analyze the profile, mortality and survival of cirrhotic patients submitted to liver transplantation for chronic hepatitis delta virus and compare with those transplanted by hepatitis B virus monoinfection. METHODS: Retrospective, observational and descriptive study. From May 2002 to December 2011, 629 liver transplants were performed at the Walter Cantídio University Hospital, of which 29 patients were transplanted due to cirrhosis caused by chronic delta virus infection and 40 by hepatitis B chronic monoinfection. The variables analyzed were: age, sex, MELD score, Child-Pugh score, upper gastrointestinal bleeding and hepatocellular carcinoma occurrence before the transplantation, perioperative platelet count, mortality and survival. RESULTS: The Delta Group was younger and all came from the Brazilian Amazon Region. Group B presented a higher proportion of male patients (92.5%) compared to Group D (58.6%). The occurrence of upper gastrointestinal bleeding before transplantation, MELD score, and Child-Pugh score did not show statistical differences between groups. The occurrence of hepatocellular carcinoma and mortality were higher in the hepatitis B Group. The survival in 4 years was 95% in the Delta Group and 75% in the B Group, with a statistically significant difference (P=0.034). Patients with hepatitis delta presented more evident thrombocytopenia in the pre-transplantation and in the immediate postoperative period. CONCLUSION: The hepatitis by delta virus patients who underwent liver transplantation were predominantly male, coming from the Brazilian Amazon region and with similar liver function to the hepatitis B virus patients. They had a lower incidence of hepatocellular carcinoma, more marked perioperative thrombocytopenia levels and frequent episodes of upper gastrointestinal bleeding. Patients with hepatitis by delta virus had lower mortality and higher survival than patients with hepatitis B virus.

RESUMO CONTEXTO: A região Amazônica é uma das principais áreas endêmicas da hepatite delta no mundo e a única relacionada com a presença do genótipo 3 do vírus delta. OBJETIVO: Analisar o perfil, mortalidade e sobrevida dos pacientes cirróticos submetidos a transplante hepático por hepatite crônica pelo vírus delta e comparar com os transplantados pela monoinfecção do vírus da hepatite B. MÉTODOS: Estudo retrospectivo, observacional e descritivo. Entre maio de 2002 a dezembro de 2011, foram realizados 629 transplantes de fígado no Hospital Universitário Walter Cantídio, dos quais 29 pacientes foram transplantados por cirrose causada pela infecção crônica do vírus delta e 40 pela monoinfecção crônica da hepatite B. As variáveis analisadas foram: origem, idade, sexo, escore de MELD, classificação de Child-Pugh, ocorrência de hemorragia digestiva alta e carcinoma hepatocelular antes do transplante, número de plaquetas perioperatória, mortalidade e sobrevida. RESULTADOS: O Grupo Delta foi mais jovem e todos oriundos da região Amazônica Brasileira. O Grupo B apresentou maior proporção de pacientes do sexo masculino (92,5%) em relação ao Grupo D (58,6%). A ocorrência de hemorragia digestiva alta antes do transplante, escore de MELD e classificação de Child-Pugh não obtiveram diferenças estatísticas entre os grupos. A ocorrência de carcinoma hepatocelular e a mortalidade foram maiores no grupo com hepatite B. A sobrevida em 4 anos foi de 95% no Grupo delta e 75% no Grupo B com diferença estatisticamente significante (P=0,034). Pacientes com hepatite delta, apresentaram mais acentuada plaquetopenia no pré-transplante e no pós-operatório imediato. CONCLUSÃO: Os pacientes com hepatite por vírus delta submetidos ao transplante hepático eram predominantemente homens, vindos da região da Amazônia brasileira e com função hepática semelhante a dos pacientes com vírus da hepatite B. Apresentavam menor incidência de carcinoma hepatocelular, níveis de trombocitopenia perioperatória mais acentuados e episódios frequentes de hemorragia digestiva alta. Os pacientes com hepatite por vírus delta apresentaram menor mortalidade e maior sobrevida que os pacientes com vírus da hepatite B.

Nonalcoholic steatohepatitis in posttransplantation liver: Review article / Esteato-hepatite não alcoólica no pós-transplante de fígado: artigo de revisão

Summary Introduction: Nonalcoholic steatohepatitis (NASH) associated or not with cirrhosis is the third leading indication for liver transplantation (LT) around the world. After transplants, NASH has a high prevalence and occurs as both recurrent and de novo manifestations. De novo NASH can also occur in allografts of patients transplanted for non-NASH liver disease. Objective: To evaluate recurrent or de novo NASH in post-LT patients. Method: A literature review was performed using search engines of indexed scientific material, including Medline (by PubMed), Scielo and Lilacs, to identify articles published in Portuguese and English until August 2016. Eligible studies included: place and year of publication, prevalence, clinical characteristics, risk factors and survival. Results: A total of 110 articles were identified and 63 were selected. Most of the studies evaluated recurrence and survival after LT. Survival reached 90-100% in 1 year and 52-100% in 5 years. Recurrence of NAFLD (steatosis) was described in 15-100% and NASH, in 4-71%. NAFLD and de novo NASH were observed in 18-67% and 3-17%, respectively. Metabolic syndrome, diabetes mellitus, dyslipidemia and hypertension were seen in 45-58%, 18-59%, 25-66% and 52-82%, respectively. Conclusion: After liver transplants, patients present a high prevalence of recurrent and de novo NASH. They also show a high frequence of metabolic disorders. Nevertheless, these alterations seem not to influence patient survival.

Resumo Introdução: A doença hepática gordurosa não alcoólica (DHGNA) é a terceira causa de transplante hepático no mundo. Tem elevada prevalência após transplante hepático (TH) e é representada pela recorrência da esteato-hepatite (NASH), ou por NASH de novo, que ocorre em pacientes transplantados por outra etiologia. Objetivo: Realizar uma revisão da literatura para avaliar a relevância da recorrência ou do NASH de novo em pacientes transplantados de fígado. Método: Realizada revisão da literatura através de artigos indexados no Medline, Scielo e Lilacs até 2016 publicados em inglês e português. Foram considerados elegíveis estudos que incluíram local e ano de publicação, prevalência e características clínicas dos pacientes. Resultados: Foram identificados 110 artigos e selecionados 63, que avaliaram a recorrência de NASH, NASH de novo e sobrevida após o TH. A sobrevida foi de 90% a 100% em um ano e de 52-100% em 5 anos. A recorrência de esteatose variou de 15-100% e a de NASH de 4-71%, enquanto esteatose e NASH de novo variaram de 18-67% e 3-17%, respectivamente. A frequência de síndrome metabólica, diabetes, dislipidemia e hipertensão variaram de 45-58%, 18-59%, 25-66% e 52-82%, respectivamente. Conclusão: No pós-transplante de fígado, os pacientes apresentam elevada prevalência de recorrência, de NASH de novo e de distúrbios metabólicos. Entretanto, essas alterações parecem não influenciar a sobrevida dos pacientes.

Liver transplantation for acute liver failure due to antitubercular drugs - a single-center experience

OBJECTIVES: Patients receiving treatment for tuberculosis are at risk of developing acute liver failure due to the hepatotoxicity of antitubercular drugs. We aimed to describe our experience with liver transplantation from deceased donors in this situation. METHODS: We identified patients undergoing transplantation for acute liver failure due to antitubercular drugs in our prospectively maintained database. RESULTS: Of 81 patients undergoing transplantation for acute liver failure, 8 cases were attributed to antitubercular drugs during the period of 2006-2016. Regarding the time of tuberculosis treatment until the onset of jaundice, patients were on antitubercular drugs for a mean of 64.7 days (21-155 days). The model for end-stage liver disease (MELD) score of patients ranged from 32 to 47 (median 38), and seven patients underwent transplantation under vasopressors. The 1-year survival was 50%. Three patients died during the week following transplantation due to septic shock (including a patient with acute liver failure due to hepatic/disseminated tuberculosis), and the remaining patient died 2 months after transplantation due to pulmonary infection. There were 2 cases of mild rejection and 1 case of moderate rejection. Of the surviving patients, all were considered cured of tuberculosis after alternative drugs were given. CONCLUSION: Patients arrived very sick and displayed poor survival after deceased donor transplantation.

Current management of biliary atresia based on 35 years of experience at a single center

OBJECTIVE: The prognosis of patients with biliary atresia undergoing Kasai portoenterostomy is related to the timing of the diagnosis and the indication for the procedure. The purpose of the present study is to present a practical flowchart based on 257 children who underwent Kasai portoenterostomy. METHODS: We conducted a retrospective cohort study of patients who underwent Kasai portoenterostomy between 1981 and 2016. RESULTS: During the first period (1981 to 2009), 230 infants were treated, and the median age at the time of surgery was 84 days; jaundice was resolved in 77 patients (33.5%). During the second period, from 2010 to 2016, a new diagnostic approach was adopted to shorten the wait time for portoenterostomy; an ultrasonography examination suggestive of the disease was followed by primary surgical exploration of the biliary tract without complementary examination or liver biopsy. Once the diagnosis of biliary atresia was confirmed, a portoenterostomy was performed during the same surgery. During this period, 27 infants underwent operations; the median age at the time of surgery was 66 days (p<0.001), and jaundice was resolved in 15 patients (55.6% - p=0.021), with a survival rate of the native liver of 66.7%. CONCLUSION: Primary surgical exploration of the biliary tract without previous biopsy was effective at improving the prognostic indicators of patients with biliary atresia undergoing Kasai portoenterostomy.

Liver Transplantation for Hepatocellular Carcinoma: Impact of Wait Time at a Single Center

ABSTRACT Introduction and aim. Liver transplantation (LT) provides durable survival for hepatocellular carcinoma (HCC). However, there is continuing debate concerning the impact of wait time and acceptable tumor burden on outcomes after LT. We sought to review outcomes of LT for HCC at a single, large U.S. center, examining the influence of wait time on post-LT outcomes. Material and methods. We reviewed LT for HCC at Mayo Clinic in Florida from 1/1/2003 until 6/30/2014. Follow up was updated through 8/1/ 2015. Results. From 2003-2014,978 patients were referred for management of HCC. 376 patients were transplanted for presumed HCC within Milan criteria, and the results of these 376 cases were analyzed. The median diagnosis to LT time was 183 days (8 - 4,337), and median transplant list wait time was 62 days (0 -1815). There was no statistical difference in recurrence-free or overall survival for those with wait time of less than or greater than 180 days from diagnosis of HCC to LT. The most important predictor of long term survival after LT was HCC recurrence (HR: 18.61, p < 0.001). Recurrences of HCC as well as survival were predicted by factors related to tumor biology, including histopathological grade, vascular invasion, and pre-LT serum alpha-fetoprotein levels. Disease recurrence occurred in 13%. The overall 5-year patient survival was 65.8%, while the probability of 5-year recurrence-free survival was 62.2%. Conclusions. In this large, single-center experience with long-term data, factors of tumor biology, but not a longer wait time, were associated with recurrence-free and overall survival.

Clinical Impact of Portal Vein Thrombosis Prior to Liver Transplantation: A Retrospective Cohort Study

ABSTRACT Introduction. To identify the impact of portal vein thrombosis (PVT) and associated medical and surgical factors on outcomes post liver transplant (LT). Material and methods. Two analyses were performed. Analysis One: cohort study of 505 consecutive patients who underwent LT (Alberta) between 01/2002-12/2012. PVT was identified in 61 (14%) patients. Analysis Two: cohort study of 144 consecutive PVT patients from two sites (Alberta and London) during the same period. Cox multivariable survival analysis was used to identify independent associations with post-LT mortality. Results. In Analysis One (Alberta), PVT was not associated with post-LT mortality (log rank p = 0.99). On adjusted analysis, complete/occlusive PVT was associated with increased mortality (Hazard Ratio (HR) 8.4, p < 0.001). In Analysis Two (Alberta and London), complete/occlusive PVT was associated with increased mortality only on unadjusted analysis (HR 3.7, p = 0.02). On adjusted analysis, Hepatitis C (HR 2.1, p = 0.03) and post-LT portal vein re-occlusion (HR 3.2, p = 0.01) were independently associated with increased mortality. Conclusion: Well-selected LT patients who had PVT prior to LT had similar post-LT outcomes to non-PVT LT recipients. Subgroups of PVT patients who did worse post-LT (complete/occlusive thrombosis pre-LT, Hepatitis C or post-LT portal vein re-occlusion) warrant closer evaluation in listing and management post-LT.

Survival benefits of interferon-based therapy in patients with recurrent hepatitis C after orthotopic liver transplantation

Recurrent hepatitis C after orthotopic liver transplantation (OLT) is universal and can lead to graft failure and, consequently, reduced survival. Hepatitis C treatment can be used to prevent these detrimental outcomes. The aim of this study was to describe rates of hepatitis C recurrence and sustained virological response (SVR) to interferon-based treatment after OLT and its relationship to survival and progression of liver disease through retrospective analysis of medical records of 127 patients who underwent OLT due to cirrhosis or hepatocellular carcinoma secondary to chronic hepatitis C between January 2002 and December 2013. Fifty-six patients were diagnosed with recurrent disease, 42 started interferon-based therapy and 37 completed treatment. Demographic, treatment- and outcome-related variables were compared between SVR and non-responders (non-SVR). There was an overall 54.1% SVR rate with interferon-based therapies. SVR was associated with longer follow-up after treatment (median 66.5 vs 37 months for non-SVR, P=0.03) and after OLT (median 105 vs 72 months, P=0.074), and lower rates of disease progression (15 vs 64.7%, P=0.0028) and death (5 vs 35.3%, P=0.033). Regardless of the result of therapy (SVR or non-SVR), there was a significant difference between treated and untreated patients regarding the occurrence of death (P<0.001) and months of survival (P<0.001). Even with suboptimal interferon-based therapies (compared to the new direct-acting antivirals) there is a 54.1% SVR rate to treatment. SVR is associated with improved survival and reduced risks of clinical decompensation, loss of the liver graft and death.

Thrombin activatable fibrinolysis inhibitor como preditor de sangramento no transplante hepático: estudo piloto observacional / Thrombin activatable fibrinolysis inhibitor as a bleeding predictor in liver transplantation: a pilot observational study

RESUMO Objetivo: Correlacionar os níveis de thrombin activatable fibrinolysis inhibitor no pós-operatório imediato e com 24 horas de pós-operatório com o volume de sangramento tansoperatório. Métodos: Foram analisados vinte e um pacientes alocados imediatamente antes do transplante hepático (eletivo ou de urgência), com coleta de amostras sanguíneas para análise de thrombin activatable fibrinolysis inhibitor em três diferentes momentos: imediatamente antes do transplante hepático (thrombin activatable fibrinolysis inhibitor pré-operatório), imediatamente após o procedimento cirúrgico (thrombin activatable fibrinolysis inhibitor pós-operatório imediato) e após 24 horas do final da cirurgia (thrombin activatable fibrinolysis inhibitor 24 horas pós-operatório). O principal desfecho do estudo foi correlacionar os níveis de thrombin activatable fibrinolysis inhibitor pré-operatório e de thrombin activatable fibrinolysis inhibitor pós-operatório imediato com perda sanguínea no transoperatório. Resultados: Houve correlação entre thrombin activatable fibrinolysis inhibitor pré-operatório e o volume de sangramento (ρ = -0,469; p = 0,05), mas não de thrombin activatable fibrinolysis inhibitor pós-operatório imediato (ρ = -0,062; p = 0,79). Em análise de regressão linear, nenhuma das variáveis incluídas (hemoglobina pré, fibrinogênio pré e thrombin activatable fibrinolysis inhibitor pré-operatório) se mostrou preditor de sangramento. Houve tendência semelhante na variação entre os níveis de thrombin activatable fibrinolysis inhibitor durante os três diferentes momentos e os níveis de fibrinogênio. Pacientes que evoluíram a óbito em até 6 meses (14,3%) apresentaram níveis diminuídos de thrombin activatable fibrinolysis inhibitor pré-operatório e de thrombin activatable fibrinolysis inhibitor pós-operatório imediato, comparando-se aos sobreviventes (pré-operatório: 1,3 ± 0,15 versus 2,55 ± 0,53; p = 0,06; e pós-operatório imediato: 1,2 ± 0,15 versus 2,5 ± 0,42; p = 0,007). Conclusão: Houve correlação moderada entre thrombin activatable fibrinolysis inhibitor pré-operatório e o sangramento transoperatório em transplante hepático, porém seu papel preditivo independente de outras variáveis ainda permaneceu incerto. Thrombin activatable fibrinolysis inhibitor pré-operatório e pós-operatório imediato podem ter um papel na avaliação da sobrevida dessa população, necessitando-se confirmar em novos estudos, de maior tamanho amostral.

ABSTRACT Objective: To correlate the levels of thrombin activatable fibrinolysis inhibitor in the immediate postoperative period and at 24 hours postoperatively with the volume of intraoperative bleeding. Methods: Twenty-one patients allocated immediately before (elective or emergency) liver transplantation were analyzed. Blood samples were collected for thrombin activatable fibrinolysis inhibitor analysis at three different time points: immediately before liver transplantation (preoperative thrombin activatable fibrinolysis inhibitor), immediately after the surgical procedure (immediate postoperative thrombin activatable fibrinolysis inhibitor), and 24 hours after surgery (thrombin activatable fibrinolysis inhibitor 24 hours after surgery). The primary outcome of the study was to correlate the preoperative and immediate postoperative levels of thrombin activatable fibrinolysis inhibitor with intraoperative blood loss. Results: There was a correlation between the preoperative thrombin activatable fibrinolysis inhibitor levels and bleeding volume (ρ = -0.469; p = 0.05) but no correlation between the immediate postoperative thrombin activatable fibrinolysis inhibitor and bleeding volume (ρ = -0.062; p = 0.79). No variable included in the linear regression analysis (prehemoglobin, prefibrinogen and preoperative thrombin activatable fibrinolysis inhibitor) was a bleeding predictor. There was a similar trend in the variation between the levels of thrombin activatable fibrinolysis inhibitor at the three different time points and fibrinogen levels. Patients who died within 6 months (14.3%) showed decreased preoperative and immediate postoperative levels of thrombin activatable fibrinolysis compared with survivors (preoperative: 1.3 ± 0.15 versus 2.55 ± 0.53, p = 0.06; immediate postoperative: 1.2 ± 0.15 versus 2.5 ± 0.42, p = 0.007). Conclusion: There was a moderate correlation between preoperative thrombin activatable fibrinolysis inhibitor and intraoperative bleeding in liver transplantation patients, although the predictive role of this variable independent of other variables remains uncertain. Preoperative and immediate postoperative thrombin activatable fibrinolysis inhibitor levels may have a role in the survival prognosis of this population; however, this possibility requires confirmation in further studies with larger sample sizes.

Técnicas y medidas tendientes a disminuir el sangrado y el consumo de hemocomponentes en trasplante hepático. Evaluación de los primeros dos años de la Unidad Bi-Institucional de Trasplante Hepático en la especialidad Medicina Transfusional y Hemoterapia / Techniques and measures geared to reducing bleeding and the consumption of hemocomponents in liver transplant. Evaluation of the first two years at the Bi-Institutional Transplant Unit in the Transfusion Medicine and Hemotherapy specialization. Results of the participation of the Transfusion Medicine Department on the indicatio of deplasmatized bloodduring heart surgery preoperative period

Introducción: el trasplante hepático (TH) es el único tratamiento definitivo para la enfermedad hepática terminal crónica y patologías que no cuentan con otra alternativa terapéutica. El sangrado y el consumo de hemocomponentes se ha vinculado al descenso de la sobrevida del injerto y del paciente. Objetivo: evaluar los resultados en el consumo de hemocomponentes con la utilización de medidas y técnicas tendientes a minimizar el sangrado. Estimar la sobrevida. Material y método: se realiza un estudio descriptivo, observacional, retrospectivo de los primeros 31 pacientes sometidos a TH. Para la búsqueda de asociación entre variables de tipo cualitativo se utilizó test de chi cuadrado para un nivel de significación ?= 0,05, para el análisis de sobrevida fue utilizado Kaplan-Meyer. Resultados: se diseñó un score para analizar el consumo de hemocomponentes; en cinco pacientes (16,1%) no se transfundieron unidades de sangre desplasmatizada (u SD) y en 58,1% se consumieron de 1 a 4 u SD, con un promedio de 3,7 ± 0,6. Un solo paciente (3,2%) se trasplantó sin transfusión de hemocomponentes. A los seis meses la sobrevida corresponde a 81,3%, con un total de cinco eventos, permaneciendo vivos al final del estudio 26 pacientes. Conclusiones: las medidas para disminuir el sangrado y los requerimientos transfusionales fueron efectivos. Los resultados fueron aceptables, cercanos a los publicados a nivel internacional.

Abstract Introduction: liver transplant is the only final treatment for chronic terminal liver disease and other conditions that have no alternative therapies. Bleeding and the hemocomponents consumption has been associated to reduction of graft survival and patient. Objective: to evaluate results in hemocomponents consumption with the application of measures and techniques that aim to minimize bleeding. To estimate survival time. Method: descriptive, observational, retrospective study of the first 31 patients who had undergone liver transplant. A chi square test was used to find the qualitative variables association, significance level ? = 0.05, the Kaplan Meyer test was used to analyse survival. Results: a score was designed to analyse hemocomponent consumption, no deplasmatized blood units were transfused in 5 patients (16.1%), and 1 to 4 deplasmatized blood units were consumed in 58.1%, with a 3.7 ± 0.6 average. A single patient (3.2%) was transplanted with no hemocomponent transfusion. Upon six months, survival represents 81.3%, with a total of five events, 26 patients being alive towards the end of the study. Conclusions: measures to diminish bleeding and transfusion requirements were effective. Results were acceptable, similar to those published globally.

Resumo Introdução: o transplante hepático (TH) é o único tratamento definitivo para a doença hepática terminal crônica e outras patologias que não contam com alternativas terapêuticas. O sangramento e o consumo de hemocomponentes foram vinculados à diminuição da sobrevida do enxerto e do paciente. Objetivo: avaliar o consumo de hemocomponentes utilizando medidas e técnicas que buscam minimizar o sangramento. Estimar a sobrevida. Material e método: estudo descritivo, observacional, retrospectivo dos primeiros 31 pacientes submetidos à TH. Para buscar a associação entre variáveis de tipo qualitativo foi utilizado o teste do , com um nível de significância ? = 0,05; para a análise de sobrevida foi utilizado o teste de Kaplan Meyer. Resultados: foi elaborado um índice para analisar o consumo de hemocomponentes; cinco pacientes (16,1%) não receberam unidades de sangue desplasmatizada (u SD) e 58,1% consumiram de 1 a 4 u SD, com uma média de 3,7 ± 0,6. Somente um (3,2%) foi transplantado sem transfusão de hemocomponentes. A sobrevida aos seis meses foi de 81,3%, com um total de cinco eventos, permanecendo vivos ao final do estudo 26 pacientes. Conclusões: as medidas para diminuir o sangramento e os requerimentos transfusionais foram eletivas. Os resultados foram aceitáveis, próximos aos valores publicados a nível internacional.

Model for End-Stage Liver Disease, Model for Liver Transplantation Survival and Donor Risk Index as predictive models of survival after liver transplantation in 1,006 patients

OBJECTIVES: Liver transplantation has not increased with the number of patients requiring this treatment, increasing deaths among those on the waiting list. Models predicting post-transplantation survival, including the Model for Liver Transplantation Survival and the Donor Risk Index, have been created. Our aim was to compare the performance of the Model for End-Stage Liver Disease, the Model for Liver Transplantation Survival and the Donor Risk Index as prognostic models for survival after liver transplantation. METHOD: We retrospectively analyzed the data from 1,270 patients who received a liver transplant from a deceased donor in the state of São Paulo, Brazil, between July 2006 and July 2009. All data obtained from the Health Department of the State of São Paulo at the 15 registered transplant centers were analyzed. Patients younger than 13 years of age or with acute liver failure were excluded. RESULTS: The majority of the recipients had Child-Pugh class B or C cirrhosis (63.5%). Among the 1,006 patients included, 274 (27%) died. Univariate survival analysis using a Cox proportional hazards model showed hazard ratios of 1.02 and 1.43 for the Model for End-Stage Liver Disease and the Model for Liver Transplantation Survival, respectively (p<0.001). The areas under the ROC curve for the Donor Risk Index were always less than 0.5, whereas those for the Model for End-Stage Liver Disease and the Model for Liver Transplantation Survival were significantly greater than 0.5 (p<0.001). The cutoff values for the Model for End-Stage Liver Disease (≥29.5; sensitivity: 39.1%; specificity: 75.4%) and the Model for Liver Transplantation Survival (≥1.9; sensitivity 63.9%, specificity 54.5%), which were calculated using data available before liver transplantation, were good predictors of survival after liver transplantation (p<0.001). CONCLUSIONS: The Model for Liver Transplantation Survival displayed similar death prediction ...

New concepts and outcomes for children with hepatoblastoma based on the experience of a tertiary center over the last 21 years

OBJECTIVE: The aim of this study was to summarize the experience of a tertiary center in treating hepatoblastoma for the last 21 years. PATIENTS AND METHODS: Fifty-eight cases were included. The tumor extent and prognosis were assessed using the PRETEXT system. The following data were analyzed: age at diagnosis, comorbidities, prematurity, treatment modalities, histopathological findings, surgical details and complications, treatment outcomes, chemotherapy schedules, side effects and complications. Treatment outcomes included the occurrence of local or distant recurrence, the duration of survival and the cause of death. The investigation methods were ultrasonography, CT scan, serum alpha-fetoprotein level measurement and needle biopsy. Chemotherapy was then planned, and the resectability of the tumor was reevaluated via another CT scan. RESULTS: The mean numbers of neoadjuvant cycles and postoperative cycles of chemotherapy were 6±2 and 1.5±1.7, respectively. All children except one were submitted for surgical resection, including 50 partial liver resections and 7 liver transplantations. Statistical comparisons demonstrated that long-term survival was associated with the absence of metastasis (p=0.04) and the type of surgery (resection resulted in a better outcome than transplantation) (p=0.009). No associations were found between vascular invasion, incomplete resection, histological subtype, multicentricity and survival. The overall 5-year survival rate of the operated cases was 87.7%. CONCLUSION: In conclusion, the experience of a Brazilian tertiary center in the management of hepatoblastoma in children demonstrates that long survival is associated with the absence of metastasis and the type of surgery. A multidisciplinary treatment involving chemotherapy, surgical resection and liver transplantation (including transplantations using tissue from living donors) led to good outcomes and survival indexes. .

Tumores malignos de novo en el trasplante hepático experiencia de un centro en la Argentina

El objetivo del presente trabajo ha sido evaluar la incidencia y las características clínicas de los tumores aparecidos de novo en los pacientes sometidos a trasplante hepático, como así también su supervivencia. Para ello, analizamos en forma retrospectiva los 168 trasplantes hepáticos realizados en 159 pacientes adultos en el período mayo 2006 hasta mayo 2014, encontrando una incidencia de neoplasia de novo de 7.5% (n = 12). La edad media en el momento del diagnóstico fue de 63 ± 7 años. Las neoplasias más frecuentes fueron las de piel no melanoma y adenocarcinomas. El 50% de las neoplasias se desarrollaron en el segundo y tercer año postrasplante. El tipo de inmunosupresión no influyó en el tipo de tumor; sin embargo, debemos destacar que la mayor parte de los pacientes recibieron tacrolimus, micofenolato y/o corticoides. El tiempo medio de seguimiento tras el diagnóstico del tumor fue 25 ± 29 meses (0-76), y la tasa de mortalidad fue de un 41% (5/12 pacientes IC95%,15-72).La supervivencia global luego del trasplante a 1 y 5 años, calculada por análisis de Kaplan-Meier, fue de 83 y 55%, respectivamente. Los tumores de novo son frecuentes luego del trasplante hepático y presentan un patrón evolutivo diferente al de la población general. Teniendo en cuenta esta evolución más agresiva, es fundamental el seguimiento periódico en estos pacientes para realizar un diagnóstico lo más precoz posible.

The aim of the present study was to evaluate the incidence and clinical features of de novo tumors in patients undergoing liver transplantation in our center as well as to assess survival. We retrospectively analyzed 168 liver transplantations (159 patients) performed from May 2006 to May 2014. The incidence of de novo tumors was 7.5% (n = 12). The mean age at diagnosis was 63 ± 7 years. The most frequent neoplasms were non melanoma skin tumors and adenocarcinomas. Fifty percent of the tumors developed in the second and third year after transplantation. Type of immunosuppression did not influence tumoral type, although most patients receive tacrolimus in combination with mycofenolate and/or corticoids. The mean duration of follow-up after diagnosis of the tumor was 25 ± 29 months (range 0-76) and the mortality was 41%. The actuarial probability of survival at 1 and 5 years was 83 and 55%, respectively. De novo tumors are frequent after liver transplantation and their clinical course differs from that in the general population. Because their clinical course is more aggressive, regular follow up of these patients is essential for early diagnosis.

Frequency of and factors associated with vascular complications after pediatric liver transplantation / Frequência e fatores relacionados a complicações vasculares após transplante hepático pediátrico

OBJECTIVE: to evaluate the frequency and factors associated with vascular complications after pediatric liver transplantation. METHOD: risk factors were evaluated in 99 patients under 18 years of age with chronic liver disease who underwent deceased donor liver transplantation (DDLT) between March of 1995 and November of 2009 at the Hospital de Clínicas de Porto Alegre, Brazil. The variables analyzed included donor and recipient age, gender, and weight; indication for transplant; PELD/MELD scores; technical aspects; postoperative vascular complications; and survival. RESULTS: vascular complications occurred in 19 patients (19%). Arterial events were most common, occurred earlier in the postoperative period, and were associated with high graft loss and mortality rates. In the multivariate analysis, the following factors were identified: portal vein diameter < 3 mm, donor-to-recipient body weight ratio (DRWR), prolonged ischemic time, and use of arterial grafts. CONCLUSION: the choice of treatment depends on the timing of diagnosis; however, in this study, surgical revision or correction produced worse outcomes than percutaneous angioplasty. The reduction of risk factors and early detection of vascular complications are key elements to a successful transplantation. .

OBJETIVO: avaliar a frequência e os fatores associados a complicações vasculares após transplante hepático pediátrico. MÉTODO: os fatores de risco foram avaliados em 99 pacientes com mais de 18 anos de idade comdoença hepática crônica submetidos a transplante hepático cadavérico (THC) entre marc¸o de1995 e novembro de 2009 no Hospital de Clínicas de Porto Alegre, Brasil. As variáveis analisadasincluíram: idade, sexo e peso dos doadores e receptores; indicac¸ão de transplante; escores PELD/MELD; aspectos técnicos; complicações vasculares pós-operatórias; e sobrevida. RESULTADOS: ocorreram complicações vasculares em 19 pacientes (19%). Os eventos arteriais foram mais comuns, tendo ocorrido precocemente no pós-operatório, e foram associados a altas taxas de perda do enxerto e mortalidade. Em uma análise multivariada, foram identificadosos seguintes fatores: diâmetro da veia porta < 3 mm, proporc¸ão de peso do doador/receptor (DRWR), tempo de isquemia prolongado e uso de enxertos arteriais. CONCLUSÃO: A escolha do tratamento depende do momento do diagnóstico; contudo, nessa série, a cirurgia de revisão, ou correc¸ão cirúrgica, produziu resultados piores que a angioplastia per-cutânea. A redução dos fatores de risco e a detecção precoce de complicações vasculares sãofundamentais para um transplante bem-sucedido. .

Analysis of thessurvival of cirrhotic patients nlisted for liver transplantatiion in the pre- and post-meld era in southern Brazil / Análise da sobrevida de pacientes cirróticos listados para transplante ortotópico de fígado nas eras pré e pós MELD no Sul do Brasil

Context Transplantation is the only cure for decompensated cirrhosis. Model for End-Stage Liver Disease (MELD) is used in liver allocation. Objectives Comparing survival of enlisted populations in pre- and post-MELD eras and estimating their long-term survival. Methods This is a retrospective study of cirrhotics enlisted for transplantation during pre- and post-MELD eras. Survival curves were generated using Kaplan-Meier’s model. Cox’s model was used to determine risk factors for mortality. Exponential, Weibull’s, normal-log and Gompertz’s models were used to estimate long-term survival. Results The study included 162 patients enlisted in pre-MELD era and 184 in post-MELD period. Kaplan-Meier’s survival curve of patients enlisted in post-MELD era was better than that of pre-MELD period (P = 0.009). This difference remained for long-term estimates, with a survival of 53.54% in 5 years and 44.64% in 10 years for patients enlisted in post-MELD era and of 43.17% and 41.75% for pre-MELD period. Era in which patients had been enlisted (P = 0.010) and MELD score at enlistment (P<0.001) were independently associated to survival with hazard ratios of 0.664 (95% CI-confidence interval = 0.487-0.906) and 1.069 (95% CI = 1.043-1.095). Conclusions MELD-based transplantation policy is superior to chronology-based one, promoting better survival for enlisted patients, even in long-term. .

Contexto O transplante é a única cura para a cirrose descompensada. O Model for End-Stage Liver Disease (MELD) é usado na alocação de órgãos. Objetivos Comparar a sobrevida da população listada para transplante nas eras pré e pós-MELD e estimar sua sobrevida a longo prazo. Métodos Este é um estudo retrospectivo, de cirróticos listados para transplante nas eras pré e pós-MELD. Curvas de sobrevida foram criadas através do modelo de Kaplan-Meier. O modelo de Cox foi utilizada para determinar fatores de risco para mortalidade. Os modelos exponencial, Weibull, log-normal e Gompertz foram usados para estimar sobrevida de longo prazo. Resultados Incluíram-se 162 pacientes listados na era pré-MELD e 184 listados na pós-MELD. A curva de Kaplan-Meier para os pacientes listados na era pós-MELD foi melhor que a da pré-MELD (P = 0,009). Esta diferença permaneceu nas estimativas de longo prazo, com sobrevida de 53,54% em 5 anos e de 44,64% em 10 anos para pacientes listados na era pós-MELD e de 43,17% e 41,75% no período pré-MELD. A era em que os pacientes eram listados (P = 0,010) e o MELD de inscrição (P<0,001) estiveram associados de maneira independente à sobrevida, com razão de riscos de 0,664 (intervalo de confiança-IC 95% = 0,487-0,906) e de 1,069 (IC 95% = 1,043-1,095). Conclusões A política de transplantes baseada no escore MELD é superior à baseada no tempo de espera em lista, promovendo melhor sobrevida, mesmo em longo prazo. .

Trasplante hepático en pacientes con trombosis de la vena porta / Liver transplantation in patients with portal vein thrombosis

Portal vein thrombosis (PVT) is a serious complication of end-stage liver disease, representing a challenge for the liver transplantation (LT) team. The aim of this study was to analyze the results of LT in patients with PVT. Methods: All adult patients who underwent a LT from a cadaveric donor between March 1994 and March 2010 were included. PVT was categorized using the classification of Yerdel and McMaster. Results: A total of 109 LT were performed in 105 patients. PVT was found in 13 cases (12.4 percent). In 6 of them (46.2 percent), thrombosis was found preoperatively by transplant routine work up. Pre-transplant systemic anticoagulation was indicated in 3 cases. At the time of surgery, only 10 patients had persistent PVT. Grade I, II, III and IV PVT was found on 2, 3, 4 and 1 patient respectively. In the 3 cases treated with systemic anticoagulation preo-peratively, grade I (1 case) and grade II (2 cases) no thrombus was evident intraoperatively. Endovenectomy was performed in 7 cases; simple thrombectomy in one and a mesenteric vein graft was required in 2 cases. No thrombus recurrence was detected on postoperative follow-up. In-hospital mortality occurred in 2 cases with PTV grade III and IV due to medical complications. One-year patient and graft survival was 69 percent vs 79 percent in patients without PVT (p = 0,476). Conclusion: Liver transplant in patients with PVT thrombosis was not associated with a significant increased risk of mortality. Systemic anticoagulation seems to be warranted while waiting for liver transplantation.

La trombosis de la vena porta (TP) es una complicación grave de la enfermedad hepática crónica terminal. La factibilidad y pronóstico del trasplante hepático (TH) dependen de su extensión en el eje porto-mesentérico. Objetivo: Analizar los resultados del trasplante hepático en pacientes con TP. Material y Método: Estudio de cohorte no concurrente a partir de los registros clínicos de los pacientes adultos con TP sometidos a un TH entre marzo de 1994 y marzo de 2010. Las TP fueron clasificadas en cuatro grados según Yerdel y Mc Master. Resultados: De 109 TH en 105 pacientes, 13 (12,4 por ciento) tuvieron una TP; en 6 de ellos el diagnóstico fue preoperatorio (46,2 por ciento). En tres se indicó tratamiento anticoagulante vía sistêmica (TACO). En el intraoperatorio se encontró TP en 10 pacientes. La trombosis fue grado I, II, III y IV en 2, 3, 4 y 1 pacientes, respectivamente. Los 3 casos tratados con TACO tenían trombosis grado I y II; en ellos no se encontró trombosis durante el trasplante. Se realizó trombectomía simple en 1 paciente, trombectomía por eversión en 7 y un puente mesentérico-portal en 2 casos. No hubo re-trombosis. Dos pacientes (15,4 por ciento) fallecieron de complicaciones médicas con injerto funcionante. La sobrevida al año de seguimiento año fue de un 69 por ciento vs 79 por ciento en los sin TP (p = 0,476). Conclusiones: El TH en pacientes con TP no se asoció a mayor mortalidad en relación a los pacientes trasplantados sin TP. El tratamiento anticoagulante en pacientes con TP puede indicarse mientras se espera el trasplante.

Can joint analysis of postoperative MELD, base excess and blood lactate levels be used as an index of postoperative outcome for patients submitted to liver transplantation? / A análise conjunta do MELD pós-operatório, do base excess e dos níveis séricos de lactato pode ser usada como um índice prognóstico para pacientes submetidos a transplante de fígado?

PURPOSE: The objective of the present study was to evaluate the postoperative levels of classical or pure MELD and changes in lactate or base excess (BE) levels as possible predictive factors of the type of outcome of patients submitted to orthotopic liver trasplantation (OLT). METHODS: The study was conducted on 60 patients submitted to OLT at the University Hospital, Faculty of Medicine of Ribeirão Preto, USP, between October 2008 and March 2012. The 30 latest survivor (S) and non-survivor (NS) cases were selected. All liver transplants were performed using the piggy-back technique. ALT, AST, BE and blood lactate values were determined for each group at five time points (immediate preoperative period, end of hypothermal ischemia, 5 and 60 minutes after arterial revascularization and in the immediate postoperative period, when the postoperative MELD was also calculated. RESULTS: The aminotransferases reached a maximum increase 24 hours after surgery in both the S and NS groups. There was a significantly higher increase in BE and blood lactate in the NS group, especially after 5 minutes of afterial reperfusion of the graft, p<0.05. There was no significant difference in preoperative MELD between groups (p>0.05), while the postoperative MELD was higher in the NS than in the S group (p<0.05) CONCLUSION: Joint analysis of postoperative MELD, BE and blood lactate can be used as an index of severity of the postoperative course of patients submitted to liver transplantation.

OBJETIVO: O objetivo do presente estudo é avaliar os níveis do MELD clássico ou puro pós-operatório, alterações dos níveis séricos do lactado e BE, analisando-os como possíveis fatores preditivos do tipo de sobrevida de pacientes submetidos ao transplante ortotópico de fígado (OLT). MÉTODOS: Foram analisados 60 pacientes submetidos ao OLT (técnica de piggy-back) no Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto-USP, entre Outubro 2008 e Março de 2012. Foram selecionados os 30 últimos casos de sobreviventes (S) e 30 de não-sobreviventes (NS). Avaliou-se para cada grupo, os valores ALT, AST, de base excess (BE) e lactato sanguíneos em cinco momentos (pré-operatório imediato, no final da isquemia hipotérmica, 5 e 60 minutos após a revascularização arterial e no pós-operatório imediato, quando também foi calculado o MELD pós-operatório. RESULTADOS: Com relação às aminotransferases, houve um aumento máximo após 24 horas de pós-operatório em ambos os grupos S e NS. Houve aumento significativo dos níveis de BE e lactato sanguíneo significativamente maior no grupo NS, sobretudo nos tempos após 5 minutos de reperfusão arterial do enxerto, p<0,05. Não houve diferença significativa entre o MELD pré-operatório em ambos os grupos (p>0,05). O MELD pós-operatório foi maior no grupo NS do que no grupo S (p<0,05). CONCLUSÃO: A análise conjunta do MELD pós-operatório, do BE e do lactato sanguíneo pode ser usada como índice de gravidade da evolução pós-operatória de pacientes submetidos ao OLT.